- Research works
- 3 fractional, all time
- Citations
- 6 1.9 per fractional work
- Top-10% rate
- 0.0% record average 16.5%
- Open access
- 64% world 28%
Not ranked overall: ImmuRx (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Which research topics does ImmuRx (United States) publish most on?
By volume in 2022–2025: Monoclonal and Polyclonal Antibodies Research, CAR-T cell therapy research, T-cell and B-cell Immunology and Immunotherapy and Immune Responses.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 1 works
- 2 CAR-T cell therapy research Oncology 1 works
- 3 T-cell and B-cell Immunology Immunology 0 works
- 4 Immunotherapy and Immune Responses Immunology 0 works
- 5 Immune Cell Function and Interaction Immunology 0 works
- 6 Single-cell and spatial transcriptomics Molecular Biology 0 works
- 7 HIV Research and Treatment Virology 0 works
- 8 vaccines and immunoinformatics approaches Molecular Biology 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has ImmuRx (United States)'s research output changed?
Other research institutions in Lebanon
- Dartmouth–Hitchcock Medical Center
- Dartmouth Psychiatric Research Center
- Dartmouth Institute for Health Policy and Clinical Practice
- Children's Hospital at Dartmouth Hitchcock
- Adimab (United States)
- Simbex (United States)
- Woomera Therapeutics
- DoseOptics (United States)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.